CMTC and Her2+/TN status in prediction of the clinical outcomes. Kaplan-Meier analysis was used to compare relapse-free patient survival among the CMTC-1 (C1), CMTC-2 (C2) and CMTC-3 (C3) in (A) 2,239 breast cancers overall and (B) 1,058 nonadjuvant treatment cancers, as well as in (C) Her2+/TN and non-Her2+/TN 2,239 breast cancers overall and (D) 1,058 nonadjuvant treatment cancers. The hazard ratios with 95% confidence intervals in parentheses were calculated using the Cox proportional hazards method. The P values were determined using the log-rank test. CMTC = ClinicoMolecular Triad Classification; Her2 = human epidermal growth factor receptor 2; HR = hazard ratio; TN = triple-negative.